Alembic Pharmaceuticals
APLLTD.NSAPLLTD.NS · Stock Price
Historical price data
Overview
Alembic Pharmaceuticals' mission is to accelerate access to quality, affordable medicines globally through a vertically integrated model spanning API synthesis to finished dosage forms. The company has achieved significant scale, with over $250M in annual US frontend sales, a pipeline of 252 ANDA filings, and a strategic foray into proprietary drug discovery with three disclosed NCE candidates. Its strategy balances cash-generating generics businesses with disciplined R&D investments in complex generics and novel therapeutics to drive long-term, high-margin growth.
Technology Platform
Vertically integrated pharmaceutical development and manufacturing platform encompassing advanced chemical synthesis, fermentation, formulation science, and a robust regulatory engine for generics and novel small molecules.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Bupropion HCl MR tablets 300mg | Bioequivalence | Phase 1 | |
| Fingolimod 0.5 mg capsules- Test drug | Bioequivalence | Phase 1 | |
| Lamotrigine ER tablet 50mg | Bioequivalence | Phase 1 |
Funding History
1FDA Approved Drugs
50Opportunities
Risk Factors
Competitive Landscape
Competes with large Indian generic peers (Sun Pharma, Dr. Reddy's) on cost and vertical integration. As it moves into NCE development, it faces competition from well-funded global biopharma firms, entering a higher-risk, capital-intensive arena.
Company Timeline
Founded in Vadodara, India
Initial Public Offering
FDA Approval: TRAVOPROST
FDA Approval: CARBIDOPA, LEVODOPA AND ENTACAPONE
FDA Approval: DIFLUPREDNATE